KRW 5130.0
(-1.35%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 240 Million KRW | -40.0% |
2022 | 400 Million KRW | -34.43% |
2021 | 610 Million KRW | -29.89% |
2020 | 870 Million KRW | -17.14% |
2019 | 1.05 Billion KRW | -67.23% |
2018 | 3.2 Billion KRW | -75.31% |
2017 | 12.97 Billion KRW | 0.0% |
2016 | - KRW | -100.0% |
2015 | 500 Million KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 160 Million KRW | -20.0% |
2024 Q1 | 200 Million KRW | -16.67% |
2023 Q2 | 320 Million KRW | -11.11% |
2023 FY | 240 Million KRW | -40.0% |
2023 Q4 | 240 Million KRW | -14.29% |
2023 Q3 | 280 Million KRW | -12.5% |
2023 Q1 | 360 Million KRW | -10.0% |
2022 Q2 | 1.11 Billion KRW | 40.1% |
2022 FY | 400 Million KRW | -34.43% |
2022 Q4 | 400 Million KRW | -83.75% |
2022 Q3 | 2.46 Billion KRW | 121.6% |
2022 Q1 | 793 Million KRW | 30.0% |
2021 Q4 | 610 Million KRW | -97.3% |
2021 Q2 | 740 Million KRW | -8.07% |
2021 Q1 | 805 Million KRW | -11.81% |
2021 FY | 610 Million KRW | -29.89% |
2021 Q3 | 22.62 Billion KRW | 2957.9% |
2020 Q3 | 1 Billion KRW | -8.1% |
2020 Q1 | 1.09 Billion KRW | -3.28% |
2020 FY | 870 Million KRW | -17.14% |
2020 Q2 | 1.08 Billion KRW | -0.29% |
2020 Q4 | 912.83 Million KRW | -8.77% |
2019 Q3 | 10.01 Billion KRW | 0.0% |
2019 FY | 1.05 Billion KRW | -67.23% |
2019 Q4 | 1.12 Billion KRW | -88.73% |
2019 Q1 | - KRW | -100.0% |
2018 Q4 | 3.2 Billion KRW | 0.0% |
2018 FY | 3.2 Billion KRW | -75.31% |
2017 FY | 12.97 Billion KRW | 0.0% |
2016 FY | - KRW | -100.0% |
2015 FY | 500 Million KRW | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 367.49 Million KRW | 34.692% |
InBody Co.,Ltd | 3.63 Billion KRW | 93.4% |
Curexo Inc. | 1.48 Billion KRW | 83.873% |
Seegene, Inc. | 1.42 Billion KRW | 83.139% |
i-SENS, Inc. | 45.74 Billion KRW | 99.475% |
Ray Co., Ltd. | 155.4 Million KRW | -54.44% |
Gencurix Inc. | 5.47 Billion KRW | 95.617% |
L&C Bio Co., Ltd | 541.32 Million KRW | 55.664% |